Boehringer Ingelheim Licenses Preclinical Immunometabolic Program from Sitryx Therapeutics in Deal Worth Over USD 500 Million
Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Sitryx Therapeutics (Oxford, UK) announced on 26 February 2026 that Boehringer has acquired an exclusive global license to a preclinical small molecule inhibitor program from Sitryx targeting autoimmune and inflammatory diseases. The Sitryx Therapeutics licensing deal encompasses multiple candidates and associated intellectual property within the program, which is described as a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells. Boehringer assumes full responsibility for further research, clinical development, and commercialization worldwide. Financial terms were not fully itemized, though the companies disclosed that Sitryx will receive upfront and near-term payments alongside potential development, regulatory, and commercialization milestone payments totaling more than USD 500 million, plus tiered royalties on future net sales. The upfront payment amount was not separately disclosed, nor were individual milestone categories or royalty rate tiers. No equity investment by Boehringer in Sitryx was mentioned. The deal does not appear to include option structures or co-development obligations; Sitryx's role following the transaction is limited to that of licensor, with no stated ongoing research responsibilities.
Deal Context
The licensed program consists of oral small molecule inhibitors positioned within the field of immunometabolism, an area of drug discovery focused on modulating immune cell function by targeting intracellular metabolic pathways rather than extracellular cytokines or receptors. The specific molecular target of the licensed candidates was not disclosed in the announcement. However, Sitryx's broader pipeline is built around immunometabolic targets, and the company's lead clinical asset, SYX-5219, is a PKM2 (pyruvate kinase M2) modulator. SYX-5219 is not part of the Boehringer Ingelheim immunology partnership; Sitryx retains that program for its own development. In October 2025, Sitryx received US FDA clearance of an IND application for SYX-5219 in atopic dermatitis, and in January 2026, the company announced it had dosed atopic dermatitis patients following clinical evidence of immunomodulatory activity in earlier studies. The licensed preclinical program, by contrast, remains at an earlier stage, with no registered clinical trials on ClinicalTrials.gov or the EU Clinical Trials Register as of the announcement date.
PKM2 and related immunometabolic targets have attracted research interest based on preclinical evidence that modulating glycolytic enzymes can alter the activation state of pathogenic immune cells, including Th17 cells and TLR-driven innate immune populations. Published studies have demonstrated that PKM2 activation can inhibit CD4+ T cell pathogenicity and suppress autoimmunity in animal models, while PKM2 has also been shown to contribute to TLR-mediated inflammation and autoimmunity by promoting Pyk2 activation. However, translational challenges persist; a 2021 study raised questions about the consistency of targeting glycolysis in Th17 cell-mediated autoimmunity models, noting that pharmacologic PKM2 modulation did not uniformly ameliorate disease across experimental contexts.
The Sitryx Therapeutics Boehringer collaboration represents the first transaction between the two companies. For Sitryx, the deal follows a pattern established by a 2020 exclusive global licensing and research collaboration with Eli Lilly, in which Lilly paid USD 50 million upfront and made a USD 10 million equity investment for rights to an immunometabolic program. That earlier deal progressed to clinical development, with Lilly exercising its option to SIT-011 for chronic autoimmune and inflammatory diseases in November 2023 and initiating a Phase 1 study. The Boehringer transaction, with a headline potential value exceeding USD 500 million plus royalties, represents a step-up in disclosed deal size relative to the Lilly arrangement, though differing deal structures and milestone definitions make direct comparison difficult.
For Boehringer Ingelheim, the Sitryx program adds to an active period of immune disease drug development dealmaking. In April 2025, Boehringer signed a licensing agreement with Cue Biopharma for a B cell depletion asset in immunology, with USD 12 million upfront and up to USD 345 million in milestones. In July 2025, Boehringer entered a deal with Re-Vana Therapeutics for a drug delivery platform valued at up to USD 1 billion. The Sitryx in-license extends Boehringer's preclinical immunology pipeline with a differentiated oral modality and mechanism, complementing its existing portfolio of autoimmune disease oral therapeutics candidates and injectable programs.